2024
Diffusion‐Weighted Imaging Fluid‐Attenuated Inversion Recovery Mismatch on Portable, Low‐Field Magnetic Resonance Imaging Among Acute Stroke Patients
Sorby‐Adams A, Guo J, de Havenon A, Payabvash S, Sze G, Pinter N, Jaikumar V, Siddiqui A, Baldassano S, Garcia‐Guarniz A, Zabinska J, Lalwani D, Peasley E, Goldstein J, Nelson O, Schaefer P, Wira C, Pitts J, Lee V, Muir K, Nimjee S, Kirsch J, Iglesias J, Rosen M, Sheth K, Kimberly W. Diffusion‐Weighted Imaging Fluid‐Attenuated Inversion Recovery Mismatch on Portable, Low‐Field Magnetic Resonance Imaging Among Acute Stroke Patients. Annals Of Neurology 2024, 96: 321-331. PMID: 38738750, PMCID: PMC11293843, DOI: 10.1002/ana.26954.Peer-Reviewed Original ResearchStroke patientsAcute ischemic strokeCut-pointsIschemic strokeStroke patients <Diagnosis of acute ischemic strokeSignal intensity ratioFluid-attenuated inversion recoveryAcute stroke patientsOptimal cut-pointMagnetic resonance imagingDiffusion-weighted imagingDWI-FLAIR mismatchStroke onsetTrained assessorsNational InstituteStrokeThrombolytic interventionNegative predictive valueFLAIR hyperintensitiesPatientsInterobserver agreementHyperacute strokeDiffusion-weightedPredictive value
2023
Effect of COVID-19 on Acute Ischemic Stroke Severity and Mortality in 2020: Results From the 2020 National Inpatient Sample
de Havenon A, Zhou L, Yaghi S, Frontera J, Sheth K. Effect of COVID-19 on Acute Ischemic Stroke Severity and Mortality in 2020: Results From the 2020 National Inpatient Sample. Stroke 2023, 54: e194-e198. PMID: 37021563, PMCID: PMC10121243, DOI: 10.1161/strokeaha.122.041929.Peer-Reviewed Original ResearchConceptsHealth Stroke ScaleStroke ScaleStroke severityLowest quartileCOVID-19Acute ischemic stroke outcomesAcute ischemic stroke severityHigher stroke severityHospital stroke mortalityIschemic stroke outcomeHigher National InstitutesNational Inpatient SampleCross-sectional cohortIschemic stroke severityCOVID-19 statusNational InstituteHospital mortalityAdjusted riskHospital dischargeIschemic strokeStroke outcomeStroke mortalityAIS severityInpatient SampleExposure status
2021
Acute Stroke Imaging Research Roadmap IV: Imaging Selection and Outcomes in Acute Stroke Clinical Trials and Practice
Campbell B, Lansberg M, Broderick J, Derdeyn C, Khatri P, Sarraj A, Saver J, Vagal A, Albers G, Adeoye O, Ansari S, Boltze J, Buchan A, Chaisinanunkul N, Chen C, Davis T, Ermakova T, Fisher M, Haddad W, Hill M, Houser G, Jadhav A, Kimberly W, Landen J, Liebeskind D, Lyden P, Lynch J, Mansi C, Mocco J, Nogueira R, Savitz S, Schwamm L, Sheth K, Solberg Y, Venkatasubramanian C, Warach S, Wechsler L, Zhu B, Ziogas N. Acute Stroke Imaging Research Roadmap IV: Imaging Selection and Outcomes in Acute Stroke Clinical Trials and Practice. Stroke 2021, 52: 2723-2733. PMID: 34233464, PMCID: PMC8316368, DOI: 10.1161/strokeaha.121.035132.Peer-Reviewed Original ResearchConceptsPrimary stroke centerAcute stroke clinical trialsStroke centersStroke clinical trialsReperfusion therapyClinical trialsConsensus recommendationsComprehensive stroke centerAcute stroke trialsImaging sessionOptimal imaging strategyExtended time windowStroke neurologistsAcute strokeStroke trialsImaging selectionComputed tomographyTreatment windowUS FoodDrug AdministrationNeurological disordersStroke imagingTrialsNational InstituteOptimal imaging
2019
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial
Selim M, Foster L, Moy C, Xi G, Hill M, Morgenstern L, Greenberg S, James M, Singh V, Clark W, Norton C, Palesch Y, Yeatts S, Investigators I, Dolan M, Yeh E, Sheth K, Kunze K, Muehlschlegel S, Nieto I, Claassen J, Falo C, Huang D, Beckwith A, Messe S, Yates M, O'Phelan K, Escobar A, Becker K, Tanzi P, Gonzales N, Tremont C, Venkatasubramanian C, Thiessen R, Save S, Verrault S, Collard K, DeGeorgia M, Cwiklinski V, Thompson B, Wasilewski L, Andrews C, Burfeind R, Torbey M, Hamed M, Butcher K, Sivakumar L, Varelas N, Mays-Wilson K, Leira E, Olalde H, Silliman S, Calhoun R, Dangayach N, Renvill R, Malhotra R, Kordesch K, Lord A, Calahan T, Geocadin R, Parish M, Frey J, Harrigan M, Leifer D, Mathias R, Schneck M, Bernier T, Gonzales-Arias S, Elysee J, Lopez G, Volgi J, Brown R, Jasak S, Phillips S, Jarrett J, Gomes J, McBride M, Aldrich F, Aldrich C, Kornbluth J, Bettle M, Goldstein J, Tirrell G, Shaw Q, Jonczak K. Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. The Lancet Neurology 2019, 18: 428-438. PMID: 30898550, PMCID: PMC6494117, DOI: 10.1016/s1474-4422(19)30069-9.Peer-Reviewed Original ResearchConceptsBetter clinical outcomesPhase 2 trialSerious adverse eventsRankin Scale scorePlacebo groupIntracerebral hemorrhagePrimary outcomeClinical outcomesDay 90Deferoxamine mesylateModified intentionTreat populationAdverse eventsUS National InstitutesDouble-blind phase 2 trialScale scorePhase 3 efficacy trialsModified Rankin Scale scoreEfficacy of deferoxaminePhase 3 trialSupratentorial intracerebral hemorrhageAbsolute risk differenceProportion of participantsNational InstituteIron chelator deferoxamine